Literature DB >> 19169831

Chronic lymphocytic leukemia: new concepts and emerging therapies.

Tahamtan Ahmadi1, Tapan Maniar, Stephen Schuster, Edward Stadtmauer.   

Abstract

OPINION STATEMENT: Remarkable progress in elucidating the biology of chronic lymphocytic leukemia (CLL) has been made over the last two decades. Improved understanding of CLL has lead to new prognostic tools and therapeutic options, and holds promise for eventually finding a cure for this disease. Challenges lie in incorporating the various treatment modalities, including chemotherapy, monoclonal antibodies, immunotherapeutic strategies and novel small molecules, into a comprehensive treatment strategy guided by the biological complexity of CLL.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19169831     DOI： 10.1007/s11864-008-0079-8

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  91 in total

1.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).

Authors:  Dolores Caballero; Jose A García-Marco; Rodrigo Martino; Victoria Mateos; José M Ribera; José Sarrá; Angel León; Guillermo Sanz; Javier de la Serna; Rafael Cabrera; Marcos González; Jorge Sierra; Jesús San Miguel
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

5.  Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; M Galinski; S Kempin; L Reich; B Clarkson; R A Good
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  The CAMPATH-1 antigen (CDw52).

Authors:  G Hale; M Q Xia; H P Tighe; M J Dyer; H Waldmann
Journal:  Tissue Antigens       Date:  1990-03

7.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Authors:  Fiona Murray; Nikos Darzentas; Anastasia Hadzidimitriou; Gerard Tobin; Myriam Boudjogra; Cristina Scielzo; Nikolaos Laoutaris; Karin Karlsson; Fanny Baran-Marzsak; Athanasios Tsaftaris; Carol Moreno; Achilles Anagnostopoulos; Federico Caligaris-Cappio; Dominique Vaur; Christos Ouzounis; Chrysoula Belessi; Paolo Ghia; Fred Davi; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

8.  Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.

Authors:  B D Cheson; J M Bennett; K R Rai; M R Grever; N E Kay; C A Schiffer; M M Oken; M J Keating; D H Boldt; S J Kempin
Journal:  Am J Hematol       Date:  1988-11       Impact factor: 10.047

9.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

Authors:  Taghi Manshouri; Kim-anh Do; Xuemei Wang; Francis J Giles; Susan M O'Brien; Helen Saffer; Deborah Thomas; Iman Jilani; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

10.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544
View more
  1 in total

1.  A new cellular weapon to kill leukaemic B-cells.

Authors:  Mohamed-Rachid Boulassel
Journal:  Sultan Qaboos Univ Med J       Date:  2012-04-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.